Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 14/20 | 1.00 |
| ▸ | PPARG | P37231 | 12/20 | 1.00 |
| ▸ | PPARD | Q03181 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.76 |
| ▸ | GMNN | O75496 | 1/20 | 0.76 |
| ▸ | USP2 | O75604 | 1/20 | 0.76 |
| ▸ | USP1 | O94782 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | TP53 | P04637 | 1/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.76 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.76 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.76 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gw7647 SCHEMBL361372 | 0.87 | PPARA (1.00) | PPARAPPARGPPARDALDH1A1CYP3A4 | |
| SCHEMBL22100299 | 0.86 | PPARA (0.98) | PPARAPPARGPPARDALDH1A1CYP3A4 | |
| SCHEMBL6552333 | 0.84 | PPARA (0.73) | PPARAPPARGPPARDALDH1A1CYP3A4 | |
| SCHEMBL4269105 | 0.80 | PPARA (0.65) | PPARAPPARGPPARDALDH1A1CYP3A4 | |
| SCHEMBL21569126 | 0.77 | PPARA (0.63) | PPARAPPARGPPARDALDH1A1CYP3A4 | |
| SCHEMBL6552622 | 0.76 | PPARA (0.80) | PPARAPPARGPPARDALDH1A1CYP3A4 | |
| SCHEMBL6553673 | 0.74 | PPARA (0.59) | PPARAPPARGPPARDALDH1A1CYP3A4 | |
| SCHEMBL16147851 | 0.73 | PPARA (1.00) | PPARAPPARGPPARDALDH1A1CYP3A4 | |
| SCHEMBL16147204 | 0.70 | PPARA (1.00) | PPARAPPARGPPARDALDH1A1CYP3A4 | |
| SCHEMBL16147225 | 0.70 | PPARA (1.00) | PPARAPPARGPPARDALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569640-A4 | COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA AGONISTS AND CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THERAPEUTIC USES THEREFOR | PHARMACIA CORP (US) | 2006-06-21 | — | — | EP | claimed |
| EP-1569640-A2 | COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA AGONISTS AND CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THERAPEUTIC USES THEREFOR | Pharmacia Corporation (US) | 2005-09-07 | — | — | EP | claimed |
| EP-1149063-B1 | UREIDO-THIOBUTYRIC ACID DERIVATIVES AS PPAR-AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-12-15 | — | — | EP | claimed |
| US-20030212138-A1 | Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor | PHARMACIA CORPORATION (US) | 2003-11-13 | — | — | US | claimed |
| WO-2003059294-A2 | COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA AGONISTS AND CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THERAPEUTIC USES THEREFOR | PHARMACIA CORPORATION (US) | 2003-07-24 | — | — | WO | claimed |
| EP-1149063-A2 | UREIDO-THIOBUTYRIC ACID DERIVATIVES AS PPAR-AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-10-31 | — | — | EP | claimed |
| US-6306854-B1 | ARYLTHIOALKYLACIDS AND ALKYL UREAS | GLAXOSMITHKLINE | 2001-10-23 | — | — | US | claimed |
| WO-2000023407-A2 | UREIDO-THIOBUTYRIC ACID DERIVATIVES AS PPAR-AGONISTS | GLAXO GROUP LIMITED (GB) | 2000-04-27 | — | — | WO | claimed |
| US-20090082435-A1 | Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-03-26 | — | — | US | disclosed |
| US-20080103209-A1 | Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-05-01 | — | — | US | disclosed |
| EP-1742626-A2 | COMPOUNDS AND METHODS FOR TREATING NON-INFLAMMATORY PAIN USING PPARALPHA AGONISTS | The Regents of The University of California (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2006116773-A2 | METHODS, COMPOSITIONS, AND COMPOUNDS FOR MODULATION OF MONOACYLGLYCEROL LIPASE, PAIN, AND STRESS-RELATED DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-11-02 | — | — | WO | disclosed |
| EP-1569640-A4 | COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA AGONISTS AND CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THERAPEUTIC USES THEREFOR | PHARMACIA CORP (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005115370-A2 | COMPOUNDS AND METHODS FOR TREATING NON-INFLAMMATORY PAIN USING PPARALPHA AGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-08 | — | — | WO | disclosed |
| EP-1149063-B1 | UREIDO-THIOBUTYRIC ACID DERIVATIVES AS PPAR-AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20030212138-A1 | Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor | PHARMACIA CORPORATION (US) | 2003-11-13 | — | — | US | disclosed |
| WO-2003059294-A2 | COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA AGONISTS AND CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THERAPEUTIC USES THEREFOR | PHARMACIA CORPORATION (US) | 2003-07-24 | — | — | WO | disclosed |
| EP-1149063-A2 | UREIDO-THIOBUTYRIC ACID DERIVATIVES AS PPAR-AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-10-31 | — | — | EP | disclosed |
| US-6306854-B1 | ARYLTHIOALKYLACIDS AND ALKYL UREAS | GLAXOSMITHKLINE | 2001-10-23 | — | — | US | disclosed |
| WO-2000023407-A2 | UREIDO-THIOBUTYRIC ACID DERIVATIVES AS PPAR-AGONISTS | GLAXO GROUP LIMITED (GB) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212138-A1 | Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor | PPARG, PPARA, PPARD | PPARA 2/4885PPARG 1/4885PPARD 3/4885 |
| US-20080103209-A1 | Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists | FAAH, CNR2, FAAH2 | PPARA 5/4885PPARG 6/4885PPARD 7/4885 |
| US-20090082435-A1 | Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders | MGLL, PNLIP, LIPC | PPARA 703/4885PPARG 330/4885PPARD 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.